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T Cell Expression of Granulocyte–Macrophage Colony-Stimulating Factor in
Juvenile Arthritis Is Contingent Upon Th17 Plasticity
Christopher Piper, Anne M. Pesenacker, David Bending, Balathas Thirugnanabalan, Hemlata Varsani,
Lucy R. Wedderburn, and Kiran Nistala
Objective. Granulocyte–macrophage colony stim-
ulating factor (GM-CSF) is a potent inflammatory
mediator that is responsible for recruitment and acti-
vation of innate immune cells. Recent data from murine
studies have identified Th17 cells as a key source of
GM-CSF and suggest that T cell–derived GM-CSF is
instrumental in the induction of autoimmune disease.
The present study was undertaken to analyze the ex-
pression of T cell–derived GM-CSF in the joints of
patients with juvenile idiopathic arthritis (JIA) and to
investigate the differentiation of Th17 cells and how this
relates to GM-CSF T helper cells.
Methods. Synovial fluid (SF) and peripheral
blood (PB) samples from 24 patients with JIA were
analyzed, by flow cytometry and reverse transcription–
polymerase chain reaction, for expression of GM-CSF
and the Th17 marker CD161. A cytokine capture assay
was used to purify Th17 cells and test the plasticity
of cytokine production in response to interleukin-12
(IL-12) and IL-23.
Results. The frequency of GM-CSF–producing T
helper cells was significantly enriched in SF mono-
nuclear cells compared to PB mononuclear cells from
the patients with JIA (24.1% of CD4 T cells versus
2.9%) and closely correlated with the erythrocyte sedi-
mentation rate (r2  0.91, P < 0.001). Synovial GM-
CSF T cells were predominantly CD161 and coex-
pressed interferon- (IFN), but not IL-17. Culture of
Th17 cells in the presence of IL-12 led to rapid up-
regulation of GM-CSF and IFN, recapitulating the
phenotype of GM-CSF–expressing cells within the joint.
Conclusion. Our results identify a novel outcome
of Th17 plasticity in humans that may account for the
enrichment of GM-CSF–expressing T cells in the joints
of patients with JIA. The association of GM-CSF expres-
sion with systemic inflammation highlights the potential
role of Th17-related cytokines in the pathology of JIA.
Juvenile idiopathic arthritis (JIA) is the most
common form of autoimmune rheumatic disease in
childhood, with a prevalence rate of 1/1,000 children
under the age of 16 years (1). The successful introduc-
tion of therapies targeting tumor necrosis factor 
(TNF) has led to significant improvement in JIA
outcomes. However, in one-third of patients the disease
remains resistant or only partially responsive to anti-
TNF therapy, suggesting ongoing uncontrolled immu-
nopathology that is independent of TNF (2). The
identification of a novel CD4 T cell subset expressing
interleukin-17 (IL-17) in a mouse model of arthritis led
many to suggest that these cells (Th17 cells) have a role
in human disease (3). We and others have demonstrated
major enrichment of Th17 cells in the inflamed joints of
children with JIA, with a correlation between the fre-
quency of these cells and the severity of disease (4,5). It
was therefore unexpected when data from studies of
IL-17–deficient mice suggested that IL-17 was redun-
dant for induction of autoimmunity in a mouse model of
multiple sclerosis, and that granulocyte–macrophage
colony-stimulating factor (GM-CSF) was instead neces-
sary and sufficient for disease (6,7).
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GM-CSF is similarly important in mouse models
of arthritis and is found in high concentrations in the
synovial fluid (SF) of patients with rheumatoid arthritis
and JIA (8–10) It has widespread effects, promoting
granulopoiesis and activating neutrophils, monocytes,
and macrophages that contribute to joint inflammation
and damage (9,10). Although GM-CSF is widely ex-
pressed in both stromal and hematopoietic compart-
ments, recent murine studies suggest that GM-CSF from
the hematopoietic compartment, particularly CD4 T
cells, is essential for disease (6,7,11). In mice, GM-CSF–
secreting T cells are closely linked with the Th17 lineage
downstream of retinoic acid receptor–related orphan
nuclear receptor t (RORt) (murine homolog of
RORC2), although data on transcriptional control of
GM-CSF are conflicting (6,7). Activated human IL-17
T cell clones produce GM-CSF (12), but the regulation
of GM-CSF production in terms of response to the
IL-12/IL-23 axis remains unknown, as does the exact
relationship between GM-CSF– and IL-17–secreting
cells. To date, evidence for the putative role of T
cell–derived GM-CSF in autoimmune disease comes
largely from murine studies. In the present study we
examined this issue in human autoimmune arthritis.
MATERIALS AND METHODS
Patients and controls. Samples studied were from 24
children who met the International League Against Rheuma-
tism criteria for JIA (13) (21 with oligoarticular disease, 3 with
polyarticular disease) and 13 adult healthy controls. Seventeen
of the JIA patients were female and 7 were male; the median
age was 10.8 years. The study was approved by the local ethical
review committee, and full informed consent was obtained
from patients/parents and control subjects.
Cell sorting and flow cytometry. Peripheral blood
mononuclear cells (PBMCs) and SF mononuclear cells
(SFMCs) were isolated by density centrifugation. For analysis
of T cell cytokine production, cells were cultured for 4 hours
in the presence of 50 ng/ml phorbol myristate acetate
(PMA), 500 ng/ml ionomycin, and 5 g/ml brefeldin A (Sigma-
Aldrich) before intracellular cytokine staining as previously
described (4). Antibodies against the following human proteins
were used: PC7-conjugated CD4 (Beckman Coulter),
phycoerythrin-conjugated CD161 (eBioscience), fluorescein
isothiocyanate– or v450-conjugated interferon- (IFN) (both
from BD Biosciences), Alexa Fluor 488–conjugated IL-17A
(eBioscience), and Alexa Fluor 647–conjugated GM-CSF
(eBioscience). A Live/Dead discriminant dye was used accord-
ing to the instructions of the manufacturer (Life Technolo-
gies). To capture cytokine-expressing cells, PBMCs or SFMCs
were enriched for CD4 T cells using magnetic beads (Stem-
Cell Technologies) and stimulated for 2 hours with PMA (10
ng/ml) and ionomycin (1 g/ml). IL-17–secreting CD4 T cells
were detected according to the instructions of the manufac-
turer (Miltenyi Biotec) and sorted with a flow cytometer
(FACSAria; BD PharMingen). The purity of sorted cells was
assessed by detection of intracellular cytokines after overnight
incubation in brefeldin A. Flow cytometric data were collected
on an LSRII (BD PharMingen); a minimum of 1  105 events
were collected. Data were analyzed using FlowJo (Tree Star).
Polymerase chain reaction. RNA was extracted using
TRIzol, according to the instructions of the manufacturer (Life
Technologies). Generation of complementary DNA, reverse
transcription—polymerase chain reaction, and analysis by the
Ct method were performed as previously described (14).
Primers used were as follows: actin forward 5-AGA-TGA-
CCC-AGA-TCA-TGT-TTG-AG-3, reverse 5-AGG-TCC-
AGA-CGC-AGG-ATG-3; RORC2 forward 5-GAC-CAC-
CCC-CTG-CTG-AGA-A-3, reverse 5-GAC-ATG-CGG-
CCG-AAC-TTG-A-3; T-bet forward 5-CCC-CAA-GGA-
ATT-GAC-AGT-TG-3, reverse 5-GGG-AAA-CTA-AAG-
CTC-ACA-AAC-3; and GM-CSF QuantiTect primers
(Qiagen). Levels of messenger RNA (mRNA) were normal-
ized to those of -actin mRNA.
Cell culture. Sorted cells were cultured in RPMI with
10% fetal calf serum (Life Technologies) in the presence of
IL-2 alone or in combination with IL-12 (from R&D Systems)
or IL-23 (eBioscience) (all at 10 ng/ml). On day 4, cytokine
expression was detected by flow cytometry after restimulation
with PMA and ionomycin in the presence of brefeldin A.
Statistical analysis. Data were analyzed using Graph-
Pad Prism 6. The significance of differences between group
means was assessed by one-way or two-way analysis of vari-
ance, with Bonferroni correction for multiple comparisons.
Correlations were assessed using Pearson’s correlation coeffi-
cient. P values less than 0.05 were considered significant.
RESULTS
Historically, synovial GM-CSF production has
been linked with synovial fibroblasts and innate immune
cells, chiefly monocytes and tissue macrophages (9). In
experiments focusing on the mononuclear cell compart-
ment, we analyzed unsorted SFMCs directly ex vivo and
detected significantly higher expression of GM-CSF
mRNA in SFMCs from patients with JIA than in
PBMCs from the patients (Figure 1A). To compare the
contribution of T cells and monocytes, we analyzed
GM-CSF mRNA expression in sorted synovial mono-
cytes and CD4 T cells and found that the levels were
comparable (Figure 1B), reinforcing the importance of
T cell–derived GM-CSF within the joint. The frequency
of GM-CSF–secreting T helper cells was quantified by
flow cytometry and shown to be significantly enriched
within the joint (mean frequency 24.1% of CD4 T
cells) compared to PBMCs from JIA patients or healthy
controls (2.9% and 5.4%, respectively) (Figures 1C and
D). The frequency of GM-CSF CD4 T cells correlated
directly with levels of GM-CSF protein in SF and also
with levels of inflammation as determined by the eryth-
rocyte sedimentation rate (ESR) (r2  0.91, P  0.001),
whereas the frequency of IFN T helper cells in SF did
1956 PIPER ET AL
not correlate with the ESR (r2  0.16, P  0.2) (Figures
1E and F).
In mice, GM-CSF expression is associated with
the Th17 differentiation pathway (6). This led us to
investigate whether GM-CSF secretion would be limited
to T cells expressing CD161, a cell surface C-type
lectin-like receptor that is closely associated with human
Th17 cells and RORC2 (15). We found that T cells
expressing GM-CSF were enriched for CD161 com-
pared to the total CD4 T cell population but had lower
levels of CD161 expression than IL-17 T cells (Figures
1G and H). Consistent with our previous data (14), the
proportion of T cells expressing CD161 was increased in
the joint compared to levels in PBMCs, and this was also
the case for GM-CSF T cells (Figure 1H).
Given that GM-CSF T cells were enriched
within the CD161 cell compartment, we predicted that
they may coexpress IL-17. Surprisingly, only 10% of
GM-CSF cells were found to be IL-17 (Figures 2A
and B). In contrast, GM-CSF expression showed much
greater concordance with IFN expression, and this
association was most prominent in synovial T cells; a
mean of 80.1% of GM-CSF CD4 T cells coexpressed
IFN (Figures 2C and D). Based on these findings, we
wondered whether GM-CSF could be up-regulated
within the “ex-Th17” cell population. We have previ-
ously shown that Th17 cells within the joint undergo
plasticity toward the Th1 phenotype while maintaining
CD161 expression (14). To test whether GM-CSF ex-
pression was associated with ex-Th17 cells, we deter-
mined levels of GM-CSF in CD161 and CD161 Th1
cell subsets. This confirmed that only CD161 Th1 cells
were significantly enriched for GM-CSF expression
compared to the total CD4 population (Figure 2E). To
investigate the transcriptional profile of CD161 Th1
cells, SFMCs were sorted by cytokine capture into Th17
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Figure 1. Enrichment of granulocyte–macrophage colony-stimulating factor (GM-CSF) expression within the arthritic joint. A and B, Expression
of GM-CSF mRNA (normalized to mRNA for -actin) in peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells
(SFMCs) from patients with juvenile idiopathic arthritis (JIA) (n  3) (A) and in whole SFMCs, synovial CD14 monocytes, and synovial CD4
T cells from patients with JIA (n  7) (B). Values are the mean  SEM. C, Representative dot plots of GM-CSF expression, detected by flow
cytometry, in JIA PBMCs and SFMCs following stimulation with phorbol myristate acetate and ionomycin in the presence of brefeldin A. All plots
were gated on CD4 T cells. D, GM-CSF expression in CD4 T cells (detected as described in C) in healthy control (HC) PBMCs (n  13) and
in JIA PBMCs (n  8) and SFMCs (n  13). Symbols represent individual samples; horizontal lines show the mean.   P  0.01 by one-way
analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. E, Pearson’s correlation between GM-CSF protein levels
(measured by enzyme-linked immunosorbent assay) in synovial supernatants and the frequency of GM-CSF CD4 T cells in paired SFMC
samples. F, Pearson’s correlation between the frequency of synovial interferon-–positive (IFN) or GM-CSF CD4 T cells and the serum
erythrocyte sedimentation rate (ESR) (measured at the time of therapeutic arthrocentesis). G, Representative dot plots of GM-CSF and CD161
expression, detected by flow cytometry, in CD4 T cells from JIA PBMCs and SFMCs. H, Proportion of the total CD4 T cell population and the
interleukin-17–positive (IL-17), GM-CSF, and IFN subsets expressing CD161 (detected as described in G) in JIA PBMCs (open bars) (n 
7) and SFMCs (solid bars) (n  7). Values are the mean  SEM.   P  0.01 by two-way ANOVA with Bonferroni correction for multiple
comparisons. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38647/abstract.
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cells, CD161 Th1 cells, and CD161 Th1 cells.
CD161 Th1 cells had significantly higher GM-CSF
and RORC2 expression than CD161 Th1 cells, but
equivalent levels of the Th1 transcription factor T-bet
(Figure 2F).
To test our hypothesis that Th17 cells undergo
plasticity toward an IFNGM-CSF phenotype, we
used a cytokine capture assay to purify IL-17 T helper
cells and, as a control, IL-17 T helper cells, from
healthy control PBMCs. Stimulation and culture of
IL-17 T cells in the presence of IL-2 down-regulated
IL-17 and promoted plasticity toward an intermediate
Th1/Th17 (IL-17IFN) and Th1 (IL-17IFN)
phenotype (Figure 3A). We have previously demon-
strated that IL-12 is significantly elevated in JIA SF
compared to serum (14). To better understand the
contribution of this cytokine to Th17 plasticity, we
cultured cells in the presence of recombinant IL-12. This
led to further differentiation toward Th1/Th17 and Th1
cells when compared to the results obtained after culture
with IL-2 alone. IL-23, although important for murine
Th17 plasticity, did not promote a Th1 phenotype
(Figure 3C).
To track GM-CSF expression during Th17 plas-
ticity, we stained cells for GM-CSF at baseline and after
stimulation and culture in the presence of IL-12. At
baseline, both the IL-17 and the IL-17 populations
exhibited minimal GM-CSF expression, whereas after
activation, GM-CSF was up-regulated in IL-17 cells
significantly more than in IL-17 cells (Figures 3B and
D). Most importantly, the IFNGM-CSF T cell
population identified in the joint was rapidly induced
following culture of IL-17 cells in the presence of
IL-12 (Figure 3E). Our data demonstrate that plasticity
toward a Th1 phenotype results not only in expression of
IFN, but in concomitant up-regulation of GM-CSF
expression.
DISCUSSION
GM-CSF has long been recognized as an inflam-
matory mediator in the joints of patients with inflamma-
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online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38647/abstract.
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tory arthritis. Although this has been extensively studied
during the last 2 decades (9), recent data from murine
models of autoimmunity have led to a reappraisal of the
role of T cell–derived GM-CSF and its importance in
arthritis. These data, together with the emergence of
biologic agents targeting this cytokine, make the study of
T cell GM-CSF expression and its regulation in human
arthritis both timely and important.
In the present study we demonstrated an enrich-
ment of GM-CSF–producing T helper cells in the joints
of patients with JIA and, importantly, the frequency of
these cells was directly correlated with levels of GM-CSF
protein in the joint and serum markers of disease
activity. To our knowledge, this is the first study to show
that GM-CSF–expressing T cells in human autoimmune
disease have a phenotype associated with ex-Th17 cells,
coexpressing CD161 and IFN. These ex-Th17 cells,
although lacking IL-17 expression, continue to express
high levels of the Th17 transcription factor RORC2
(5,14). It is possible that RORC2 continues to play a role
in the maintenance of GM-CSF within the ex-Th17
population. Expression of T-bet was not elevated in
synovial T cells that were enriched for GM-CSF (Figure
2F), which is consistent with results of mouse studies
showing normal GM-CSF expression in T-bet–knockout
animals (6,7).
It has previously been shown that Th17 clones
secrete GM-CSF (12), but, to our knowledge, this is the
first study to demonstrate the role of IL-12 in driving
Th17 plasticity toward a GM-CSF phenotype, and its
possible role in arthritis. Interestingly, fate mapping
studies have shown that IL-23, a member of the IL-12
cytokine family, has this effect in mice (16), while in
humans IL-23 appears to stabilize the Th17 phenotype
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Figure 3. Transition of Th17 cells toward a GM-CSF–expressing phenotype in response to IL-12. A and B, IL-17 and IL-17 CD4 T cells from
healthy control PBMCs were sorted by flow cytometry following cytokine capture and analyzed for expression of IFN and IL-17 (A) or IFN and
GM-CSF (B) at baseline and after culture for 4 days in the presence of IL-2 (alone or with IL-12) prior to restimulation with phorbol myristate
acetate and ionomycin in the presence of brefeldin A and analysis for cytokine expression. Results of a representative experiment (of 5 performed)
are shown. C, IL-17 CD4 T cells (gray bars) and IL-17 CD4 T cells (black bars) from healthy control PBMCs were cultured as described in
A (as well as with IL-2 plus IL-23), and the proportion of live cells expressing IFN but not IL-17 was determined. D and E, IL-17 CD4 T cells
(gray bars) and IL-17 CD4 T cells (black bars) from healthy control PBMCs were cultured as described in B (as well as with IL-2 plus IL-23),
and the proportion of live cells expressing GM-CSF (D) or IFN and GM-CSF (E) was determined. Values in C–E are the mean  SEM.   P 
0.05;   P  0.01, by two-way ANOVA with Bonferroni correction for multiple comparisons. See Figure 1 for definitions.
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(17). The consequences of Th17 plasticity in arthritis
were initially unclear, as the switch from IL-17 to IFN
seemed unlikely to drive significant pathology given that
administration of recombinant IFN to patients with
rheumatoid arthritis has no adverse consequences (18).
We propose that Th17 plasticity contributes to the
persistence of joint inflammation by augmenting local
levels of GM-CSF. The development of therapeutic
antibodies targeting the GM-CSF receptor -chain of-
fers a valuable opportunity to test the importance of
GM-CSF in JIA pathology, and early reports from
rheumatoid arthritis studies are encouraging (19). Al-
though our study has focused on Th17-related GM-CSF,
Th17 cells are relatively rare in the joint and GM-CSF is
also expressed by non–T cells, which suggests that
Th17-independent GM-CSF could be important as well.
Irrespective of the cellular source, receptor blockade
would abrogate the downstream actions of GM-CSF and
may be a viable therapeutic option in treatment-resistant
JIA.
In conclusion, we have identified Th17 plasticity
as a key driver of GM-CSF production within the
arthritic joint. These results and the link between syno-
vial GM-CSF enrichment and systemic inflammation
strengthen the case for initiating trials of biologic agents
that target the Th17 pathway, and in particular GM-
CSF, in juvenile idiopathic arthritis.
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